Eurofins CDMO Alphora announces the completion of a new pilot scale biologics development facility

Ontario Industry UpdatesOBIO News
Written By Arsheen Kaur

Eurofins CDMO Alphora Inc., a contract drug and manufacturing organization based in Mississauga, recently announced the successful completion of its pilot-scale biologics development facility. Spanning 3,300 square feet, the facility is dedicated to the development and scaling of monoclonal antibodies (mAbs) and other mammalian-based therapeutic proteins.

We are pleased to count Eurofins CDMO Alphora as an OBIO® member, and also as a sponsor of the OBIO® Investment Summit happening this month.

Arsheen Kaur
Previous

Swift Medical secures new financing round to further enhance its AI-based wound care technology
Next

Cohesys awarded $1.62M from MTEC to support BoneTape, a revolutionary fracture fixation technology